Explanipedia

Oral targeting tilianin nanoplatform mitigates atherosclerosis through promoting macrophage phagocytosis and anti-inflammation Open

Min Sun, Mengran Guo, Zhongshan He, Yaoyao Luo, Huiling Yang , et al. · 2025

Modulating macrophage function is an effective strategy for treating atherosclerosis. Our previous research shows that tilianin (Til) effectively regulates macrophage polarization. This immune modulation positions Til as a promising plant-…

The pharmacokinetics effects of the MCAO model on senkyunolide I in pseudo germ-free rats after oral co-administration of Chuanxiong and warfarin Open

Haigang Li, Fang Li, Yi Zhou, Zhang Xiang, Bilan Zhou , et al. · 2025

Aim To investigate the pharmacokinetics effects of a middle cerebral artery occlusion (MCAO) model on senkyunolide I (SEI) in pseudo germ-free rats after oral co-administration of Chuanxiong and warfarin. Methods Rats were divided randomly…

A novel dual-targeting strategy of nanobody-driven protein corona modulation for glioma therapy Open

Y. Zhang, Shugang Qin, Tingting Song, Zhiying Huang, Zhuanzhuan Lv , et al. · 2025

Glioma represents the most prevalent malignant tumor of the central nervous system, with chemotherapy serving as an essential adjunctive treatment. However, most chemotherapeutic agents exhibit limited ability to penetrate the blood-brain …

Oral Targeting Tilianin Nanoplatform Mitigates Atherosclerosis Through Promoting Macrophage Phagocytosis and Anti-Inflammation Open

Min Sun, Mengran Guo, Zhongshan He, Yaoyao Luo, Huiling Yang , et al. · 2025

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor Open

Ajit Regmi, Eitaro Aihara, Michael E. Christe, Gábor Varga, Thomas P. Beyer , et al. · 2024

Tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor (GIPR/GLP-1R) agonist, has, in clinical trials, demonstrated greater reductions in glucose, body weight, and triglyceride levels compared with sel…

Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein Open

Julie S. Moyers, Ryan J. Hansen, Jonathan W. Day, Craig D. Dickinson, Chen Zhang , et al. · 2022

The benefit of once-weekly basal insulin is less frequent dosing, which has the potential to reduce the barrier to injection therapy and impact patient activation, adherence and compliance, quality of life, and outcomes. Basal Insulin Fc (…

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice Open

Ricardo J. Samms, Michael E. Christe, Kyla Collins, Valentina Pirro, Brian A. Droz , et al. · 2021

Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor (GLP-1R) agonist, delivered superior glycemic control and weight loss compared with GLP-1R agonism in patients with type 2 diabetes. However, the mechanism by which tirzepatide improve…

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF) Open

Julie S. Moyers, Ryan J. Hansen, Jonathan W. Day, Craig D. Dickinson, Chen Zhang , et al. · 2021

Weekly basal insulin injections may increase treatment adherence in subjects with diabetes and an appropriately engineered weekly basal insulin may reduce daily pharmacokinetic (PK)/pharmacodynamic (PD) fluctuations compared to currently a…

In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog Open

Robyn Owens, R. J. Hansen, Steven D. Kahl, Chunhua Zhang, Xiaoping Ruan , et al. · 2016

Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice Open

Daniel A. Briere, Xiaoping Ruan, Christine C. Cheng, Angela M. Siesky, Thomas Fitch , et al. · 2015

Activation of TGR5 via bile acids or bile acid analogs leads to the release of glucagon-like peptide-1 (GLP-1) from intestine, increases energy expenditure in brown adipose tissue, and increases gallbladder filling with bile. Here, we pres…

Xiaoping Ruan YOU? Author Swipe